A comparison of visual assessment and semi-quantification for the diagnostic and prognostic use of [
Alzheimer’s disease
Cognitive decline
Tau stages
Visual rating
[18F]Flortaucipir PET
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
06 Jan 2024
06 Jan 2024
Historique:
received:
04
10
2023
accepted:
22
12
2023
medline:
6
1
2024
pubmed:
6
1
2024
entrez:
5
1
2024
Statut:
aheadofprint
Résumé
[ We included 245 individuals from the Geneva Memory Clinic who underwent [ We found good inter-rater reliability in the visual interpretation of tau Braak stages, independently from the rater's expertise (k>0.68, p<0.01). A good agreement was equally found between visual and SUVR-based classifications for tau status (k=0.67, p<0.01). All tau-assessment modalities significantly discriminated amyloid-positive MCI and demented subjects from others (AUC>0.80) and amyloid-positive from negative subjects (AUC>0.85). Linear mixed-effect models showed that tau-positive individuals presented a significantly faster cognitive decline than the tau-negative group (p<0.01), independently from the classification method. Our results show that visual assessment is reliable for defining tau status and stages in a memory clinic population. The high inter-rater reliability, the substantial agreement, and the similar diagnostic and prognostic performance of visual rating and semi-quantitative methods demonstrate that [
Identifiants
pubmed: 38182839
doi: 10.1007/s00259-023-06583-9
pii: 10.1007/s00259-023-06583-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Nat Rev Dis Prim 2015 11 [Internet]. 2015 [cited 2023 Mar 28];1:1–18. Available from: https://www.nature.com/articles/nrdp201556
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Neurology [Internet]. 1991 [cited 2023 Mar 28];41:479–479. Available from: https://n.neurology.org/content/41/4/479
Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvadó G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging [Internet]. 2022 [cited 2023 Mar 28];49:3508. Available from: /pmc/articles/PMC9308604/
Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s Dement. 2015;11:1–15.
doi: 10.1016/j.jalz.2014.07.003
Schöll M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron [Internet]. 2016 [cited 2023 Mar 28];89:971–82. Available from: https://pubmed.ncbi.nlm.nih.gov/26938442/
Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;
Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;
Boccalini C, Ribaldi F, Hristovska I, Arnone A, Peretti D, Mu L, et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Accept Publ Alzheimer’s Dement. 2023;
Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R. Tau PET imaging in neurodegenerative disorders. J Nucl Med [Internet]. 2022 [cited 2023 May 25];63:20S-26S. Available from: https://jnm.snmjournals.org/content/63/Supplement_1/20S
Baker SL, Harrison TM, Maass A, Joie R La, Jagust WJ. Effect of off-target binding on 18F-flortaucipir variability in healthy controls across the life span. J Nucl Med [Internet]. 2019 [cited 2023 Aug 1];60:1444–51. Available from: https://jnm.snmjournals.org/content/60/10/1444
Villemagne VL, Lopresti BJ, Doré V, Tudorascu D, Ikonomovic MD, Burnham S, et al. What is T+? A Gordian knot of tracers, thresholds, and topographies. J Nucl Med [Internet]. 2021 [cited 2023 May 25];62:614–9. Available from: https://jnm.snmjournals.org/content/62/5/614
Sonni I, Lesman Segev OH, Baker SL, Iaccarino L, Korman D, Rabinovici GD, et al. Evaluation of a visual interpretation method for tau-PET with 18F-flortaucipir. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2020;12.
Provost K, Iaccarino L, Soleimani-Meigooni DN, Baker S, Edwards L, Eichenlaub U, et al. Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. Available from: https://www.nitrc.org/projects/mricron
Coomans EM, de Koning LA, Rikken RM, Verfaillie SC, Visser D, Braber A den, et al. Performance of a [18F]Flortaucipir PET visual read method across the Alzheimer disease continuum and in dementia with lewy bodies. Neurology [Internet]. 2023 [cited 2023 Oct 2]; Available from: https://pubmed.ncbi.nlm.nih.gov/37748892/
Schwarz AJ, Shcherbinin S, Slieker LJ, Risacher SL, Charil A, Irizarry MC, et al. Topographic staging of tau positron emission tomography images. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2018;10:221–31.
Biel D, Brendel M, Rubinski A, Buerger K, Janowitz D, Dichgans M, et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimer’s Res Ther. 2021;13.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. Springer-Verlag; 1991:239–59.
Ribaldi F, Chicherio C, Altomare D, Martins M, Tomczyk S, Jelescu I, et al. Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. Alzheimers Res Ther [Internet]. 2021 [cited 2023 Sep 18];13. Available from: https://pubmed.ncbi.nlm.nih.gov/34034799/
Shcherbinin S, Schwarz AJ, Joshi A, Navitsky M, Flitter M, Shankle WR, et al. Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease. J Nucl Med [Internet]. 2016 [cited 2023 Jun 12];57:1535–42. Available from: https://pubmed.ncbi.nlm.nih.gov/27151986/
Rolls ET, Huang CC, Lin CP, Feng J, Joliot M. Automated anatomical labelling atlas 3. Neuroimage [Internet]. 2020 [cited 2023 Jun 12];206. Available from: https://pubmed.ncbi.nlm.nih.gov/31521825/
Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut-points for brain aging and Alzheimer’s disease. Alzheimers Dement [Internet]. 2017 [cited 2023 Jun 12];13:205. Available from: /pmc/articles/PMC5344738/
Mishra S, Gordon BA, Su Y, Christensen J, Friedrichsen K, Jackson K, et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. Neuroimage [Internet]. 2017 [cited 2023 Jun 12];161:171. Available from: /pmc/articles/PMC5696044/
Dodich A, Mendes A, Assal F, Chicherio C, Rakotomiaramanana B, Andryszak P, et al. The A/T/N model applied through imaging biomarkers in a memory clinic. Eur J Nucl Med Mol Imaging [Internet]. 2020 [cited 2023 Jun 12];47:247–55. Available from: https://pubmed.ncbi.nlm.nih.gov/31792573/
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement [Internet]. 2011 [cited 2023 Jun 12];7:270–9. Available from: https://pubmed.ncbi.nlm.nih.gov/21514249/
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7:263–9.
doi: 10.1016/j.jalz.2011.03.005
Schöll M, Ossenkoppele R, Strandberg O, Palmqvist S, Jögi J, Ohlsson T, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Brain [Internet]. 2017 [cited 2023 Aug 7];140:2286–94. Available from: https://doi.org/10.1093/brain/awx171
Baker SL, Harrison TM, Maass A, Joie R La, Jagust WJ. Effect of off-target binding on 18F-flortaucipir variability in healthy controls across the life span. J Nucl Med [Internet]. 2019 [cited 2023 Aug 2];60:1444–51. Available from: https://pubmed.ncbi.nlm.nih.gov/30877180/
Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry [Internet]. 2019 [cited 2023 Aug 2];24:1112–34. Available from: https://pubmed.ncbi.nlm.nih.gov/30635637/
Peet BT, Spina S, Mundada N, La Joie R. Neuroimaging in frontotemporal dementia: heterogeneity and relationships with underlying neuropathology. Neurotherapeutics [Internet]. 2021 [cited 2023 Nov 24];18:728. Available from: /pmc/articles/PMC8423978/
Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961–71.
doi: 10.1001/jamaneurol.2021.1858
pubmed: 34180956
pmcid: 8240013
Peretti DE, Ribaldi F, Scheffler M, Chicherio C, Frisoni GB, Garibotto V. Prognostic value of imaging-based ATN profiles in a memory clinic cohort. Eur J Nucl Med Mol Imaging [Internet]. 2023 [cited 2023 Sep 18]; Available from: https://pubmed.ncbi.nlm.nih.gov/37358619/
Lu M, Pontecorvo MJ, Devous MD, Arora AK, Galante N, McGeehan A, et al. Aggregated tau measured by visual interpretation of flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and Alzheimer disease: results from 2 phase III clinical trials. JAMA Neurol. 2021;78:445–53.
doi: 10.1001/jamaneurol.2020.5505
pubmed: 33587110
pmcid: 7885097
Barrio JR. The Irony of PET Tau Probe Specificity. J Nucl Med [Internet]. 2018 [cited 2023 Aug 3];59:115–6. Available from: https://jnm.snmjournals.org/content/59/1/115
Mormino EC, Papp K V., Rentz DM, Donohue MC, Amariglio R, Quiroz YT, et al. Early and late change on the preclinical Alzheimer’s cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimers Dement [Internet]. 2017 [cited 2023 Aug 3];13:1004–12. Available from: https://pubmed.ncbi.nlm.nih.gov/28253478/
Roalf DR, Moberg PJ, Xie SX, Wolk DA, Moelter ST, Arnold SE. Comparative accuracies of two common screening instruments for classification of Alzheimer’s disease, mild cognitive impairment, and healthy aging. Alzheimers Dement [Internet]. 2013 [cited 2023 Aug 3];9:529–37. Available from: https://pubmed.ncbi.nlm.nih.gov/23260866/